Alnylam jumps as AMVUTTRA ATTR-CM momentum and 2026 TTR outlook return to focus
Alnylam Pharmaceuticals shares rose as investors refocused on accelerating AMVUTTRA momentum in ATTR cardiomyopathy and the company’s reiterated 2026 TTR revenue outlook of $4.4–$4.7 billion. Recent investor materials and analyst commentary kept attention on a 2026 growth inflection driven by the TTR franchise.
1. What’s moving the stock
Alnylam Pharmaceuticals (ALNY) traded higher Monday, April 6, 2026, in a move that appears tied to renewed buy-side focus on the company’s transthyretin (TTR) franchise—especially AMVUTTRA uptake in ATTR cardiomyopathy (ATTR-CM)—and management’s 2026 growth framework. A recent company-led TTR-focused update highlighted ATTR-CM momentum and reiterated 2026 TTR revenue guidance of $4.4 billion to $4.7 billion, keeping the core growth narrative front-and-center for investors.
2. The key fundamentals investors are keying on
The near-term debate is whether AMVUTTRA’s ATTR-CM penetration can sustain a steep 2026 ramp despite pricing and mix headwinds. Recent analyst commentary has continued to frame 2026 as a TTR-driven acceleration year, with multiple firms pointing to the ATTR-CM launch trajectory as a primary value driver even while flagging possible soft spots near-term (including ex-U.S. dynamics and net price considerations).
3. What to watch next
With the next earnings date approaching later this month, traders will watch for updated 2026 revenue cadence expectations, new commercial metrics in ATTR-CM (starts, persistence, payer mix), and any refinement around geographic contributions. Investors will also monitor upcoming company event materials for incremental detail on demand-generation initiatives, diagnosis expansion efforts, and competitive/market-access developments in the ATTR-CM category.